A ‘mix and match’ approach to SARS-CoV-2 vaccination

Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2021-09, Vol.27 (9), p.1510-1511
Hauptverfasser:	Deming, Meagan E., Lyke, Kirsten E.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/255/2514 706/648/697 Biomedical and Life Sciences Biomedicine Cancer Research COVID-19 COVID-19 Vaccines Homology Humans Immune response Immunogenicity Infectious Diseases Metabolic Diseases Molecular Medicine mRNA Neurosciences News & Views news-and-views SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.
ISSN:	1078-8956 1546-170X 1546-170X
DOI:	10.1038/s41591-021-01463-x